<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03862716</url>
  </required_header>
  <id_info>
    <org_study_id>REMITiDegLira</org_study_id>
    <nct_id>NCT03862716</nct_id>
  </id_info>
  <brief_title>Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IDegLira</brief_title>
  <acronym>REMITiDegLira</acronym>
  <official_title>Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IDegLira (REMIT IDegLira): A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Population Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Population Health Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine whether in patients with early type 2 diabetes, a
      short-term intensive metabolic intervention comprising IDegLira, metformin, and lifestyle
      approaches will be superior to standard diabetes therapy in achieving sustained diabetes
      remission.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicentre, open-label, randomized controlled trial in 160 patients with
      recently-diagnosed T2DM. Participants will be randomized to 2 treatment groups: (a) a 16-week
      course of treatment with IDegLira, metformin and lifestyle therapy, and (b) standard diabetes
      therapy, and followed for a total of 68 weeks (1 year and 4 months). In all participants with
      HbA1C&lt;7.3% at the 16 week visit, glucose-lowering medications will be discontinued and
      participants will be encouraged to continue with lifestyle modifications and regular glucose
      monitoring. Participants with HbA1C ≥ 7.3% at this visit or who experience hyperglycemia
      relapse after stopping drugs will receive standard glycemic management as informed by the
      current Canadian Diabetes Association clinical practice guidelines.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 23, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants achieving drug-free diabetes remission</measure>
    <time_frame>28 weeks after randomization</time_frame>
    <description>Drug-free diabetes remission is defined as HbA1C &lt; 6.5 % off glucose-lowering agents for at least 12 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants achieving drug-free diabetes remission</measure>
    <time_frame>28 weeks, 40 weeks, 52 weeks and 68 weeks after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants achieving drug-free normoglycemia</measure>
    <time_frame>28 weeks, 40 weeks, 52 weeks and 68 weeks after randomization</time_frame>
    <description>defined as HbA1C &lt; 6.0% off glucose-lowering agents for at least 12 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants achieving drug-free diabetes regression</measure>
    <time_frame>28 weeks, 40 weeks, 52 weeks and 68 weeks after randomization</time_frame>
    <description>defined as HbA1C &lt;7.0% off glucose-lowering agents for at least 12 weeks.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>the time interval from randomization until any glucose lowering drug is restarted or relapse of hyperglycemia</measure>
    <time_frame>Up to week 68</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>the time interval from the 16 week visit (i.e. when glucose lowering drugs are to be stopped) until any glucose lowering drug is restarted or relapse of hyperglycemia</measure>
    <time_frame>Up to week 68</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>the change in HbA1c</measure>
    <time_frame>16, 28, 40, 52 and 68 week visit as well as the overall change</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>the change in weight</measure>
    <time_frame>16, 28, 40, 52 and 68 week visit as well as the overall change</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>the change in waist circumference</measure>
    <time_frame>16, 28, 40, 52 and 68 week visit as well as the overall change</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>the change in hip circumference</measure>
    <time_frame>16, 28, 40, 52 and 68 week visit as well as the overall change</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>the change in body mass index</measure>
    <time_frame>16, 28, 40, 52 and 68 week visit as well as the overall change</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>the change in coefficient of variation over 2 weeks (defined as 4-8 mmol/l), based on up to 2 weeks of Abbott Freestyle Libre ProTM sensor wear</measure>
    <time_frame>from randomization until the 6, 16, 28 and 52 week visit</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>the change in interquartile range over 2 weeks (defined as 4-8 mmol/l), based on up to 2 weeks of Abbott Freestyle Libre ProTM sensor wear</measure>
    <time_frame>from randomization until the 6, 16, 28 and 52 week visit</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>the change in time range over 2 weeks (defined as 4-8 mmol/l), based on up to 2 weeks of Abbott Freestyle Libre ProTM sensor wear</measure>
    <time_frame>from randomization until the 6, 16, 28 and 52 week visit</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: IDegLira - sc injection; Drug: metformin - oral administration; Drug: insulin degludec - sc injection; Behavioral: lifestyle therapy, diet and exercise</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard glycemic care as informed by the current clinical practice guidelines</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IDegLira</intervention_name>
    <description>Dose is titrated to achieve fasting normoglycemia</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>insulin degludec / liraglutide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin degludec</intervention_name>
    <description>In those who need additional insulin or who cannot tolerate IDegLira, insulin degludec will be used. Dose is titrated to achieve fasting normoglycemia.</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Dose is titrated to 2000 mg per day or maximal tolerated dose</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Lifestyle Therapy</intervention_name>
    <description>Lifestyle intervention includes individualized dietary and exercise advice targeting at least 5% weight loss with frequent visits and coaching for goal reinforcement, behavior modification and problem-solving</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>diet and exercise</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. men and women aged 30-80 years;

          2. T2D diagnosed within 5 years

          3. stable T2D drug regimen in the 8 weeks before randomization;

          4. HbA1c 6.5-9.5% on no glucose lowering drugs, or 6.5%-8.0% on up to 2 glucose lowering
             drugs;

          5. body mass index ≥ 23 kg/m2;

          6. ability and willingness to perform self-monitoring of capillary blood glucose (SMBG);

          7. willingness to wear a continuous glucose monitor on at least 3 occasions;

          8. ability and willingness to self-inject IDegLira and insulin;

          9. provision of informed consent.

        Exclusion Criteria:

          1. current use of insulin therapy;

          2. history of hypoglycemia unawareness, or severe hypoglycemia requiring assistance;

          3. history of end-stage renal disease or eGFR&lt;45 mL/min/1.73 m2 by MDRD formula;

          4. active liver disease or elevated alanine transferase (ALT) levels ≥ 2.5 times the
             upper limit of normal at the time of enrolment;

          5. history or clinical suspicion of pancreatitis or medullary thyroid cancer;

          6. diagnosis or first degree relative with Multiple Endocrine Neoplasia Type 2 (MEN2);

          7. history of diabetic retinopathy requiring photocoagulation, injection therapy or
             vitrectomy;

          8. history of cardiovascular disease (unless cleared for a moderate intensity exercise
             program by a specialist) including: i. acute coronary syndrome, hospitalization for
             unstable angina, myocardial infarction, or revascularization with coronary artery
             bypass grafting or percutaneous coronary intervention; ii. peripheral vascular
             disease, valvular heart disease, cardiomyopathy, aortic dissection, tachyarrhythmias,
             bradyarrhythmias, prior stroke or TIA; iii. prior hospitalization for heart failure;
             or iv. ECG findings concerning for ischemic heart disease (i.e. pathological Q-waves,
             ST-segment-T-wave abnormalities in contiguous leads, left anterior hemiblock, left
             bundle branch block, second or third degree atrioventricular block).

          9. history of any disease requiring frequent intermittent or continuous systemic
             glucocorticoid treatment;

         10. history of bariatric surgery, or planned bariatric surgery in the next 1.5 years;

         11. history of any major illness with a life expectancy of &lt; 3 years;

         12. history of injury or any other condition that significantly limits participant's
             ability to achieve moderate levels of physical activity;

         13. excessive alcohol intake, acute or chronic;

         14. currently pregnant, or breastfeeding, or not using a reliable method of birth control
             for the duration of the trial in all females with childbearing potential;

         15. inability to take insulin degludec, liraglutide or metformin.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zubin Punthakee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>McMaster University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hertzel Gerstein, MD</last_name>
    <role>Study Chair</role>
    <affiliation>McMaster University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stephanie Hall</last_name>
    <phone>905-521-2100</phone>
    <phone_ext>40667</phone_ext>
    <email>stephanie.hall@phri.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2T 5C7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ron Sigal, MD</last_name>
      <phone>403-955-8107</phone>
      <email>rsigal@ucalgary.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2E1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Caroline Lyster</last_name>
      <phone>780-248-1770</phone>
      <email>clyster@ualberta.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nova Scotia Health Authority</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Blaine Gallant, BScN</last_name>
      <phone>902-473-3299</phone>
      <email>blaine.gallant@nshealth.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>McMaster University</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zubin Punthakee, MD</last_name>
      <phone>905-525-9140</phone>
      <phone_ext>22205</phone_ext>
      <email>smithad@mcmaster.ca</email>
    </contact>
    <contact_backup>
      <last_name>Ada Smith</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Hospital</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4V2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamara Spaic, MD</last_name>
      <email>tamara.spaic@sjhc.london.on.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Western University</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6G 2M1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stewart Harris, MD</last_name>
      <phone>519-661-2111</phone>
      <email>Stewart.Harris@schulich.uwo.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>LMC Manna Research</name>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <zip>L6M 1M1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yaw Twum-Barima, MD</last_name>
      <phone>905-337-0040</phone>
      <email>oakvilleresearch@lmc.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4E9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Heather Lochnan, MD</last_name>
      <email>hlochnan@toh.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>February 25, 2019</study_first_submitted>
  <study_first_submitted_qc>March 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2019</study_first_posted>
  <last_update_submitted>June 3, 2019</last_update_submitted>
  <last_update_submitted_qc>June 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>IDegLira</keyword>
  <keyword>Metformin</keyword>
  <keyword>Insulin</keyword>
  <keyword>Diet</keyword>
  <keyword>Excercise</keyword>
  <keyword>Lifestyle</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Liraglutide</mesh_term>
    <mesh_term>Insulin, Long-Acting</mesh_term>
    <mesh_term>Xultophy</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

